- Home
- ONMD vs PMN Comparison
ONMD vs PMN Comparison
Compare ONMD & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- PMN
- Stock Information
- Founded
- ONMD 2006
- PMN 2004
- Country
- ONMD United States
- PMN Canada
- Employees
- ONMD N/A
- PMN N/A
- Industry
- ONMD
- PMN Pharmaceuticals and Biotechnology
- Sector
- ONMD
- PMN Health Care
- Exchange
- ONMD Nasdaq
- PMN Nasdaq
- Market Cap
- ONMD 32.5M
- PMN 29.8M
- IPO Year
- ONMD N/A
- PMN N/A
- Fundamental
- Price
- ONMD $0.70
- PMN $0.79
- Analyst Decision
- ONMD
- PMN Strong Buy
- Analyst Count
- ONMD 0
- PMN 1
- Target Price
- ONMD N/A
- PMN N/A
- AVG Volume (30 Days)
- ONMD 51.1K
- PMN 51.4K
- Earning Date
- ONMD 12-17-2024
- PMN 03-31-2025
- Dividend Yield
- ONMD N/A
- PMN N/A
- EPS Growth
- ONMD N/A
- PMN N/A
- EPS
- ONMD 0.01
- PMN N/A
- Revenue
- ONMD $957,651.00
- PMN N/A
- Revenue This Year
- ONMD N/A
- PMN N/A
- Revenue Next Year
- ONMD N/A
- PMN N/A
- P/E Ratio
- ONMD $87.64
- PMN N/A
- Revenue Growth
- ONMD 1.36
- PMN N/A
- 52 Week Low
- ONMD $0.46
- PMN $0.62
- 52 Week High
- ONMD $3.37
- PMN $2.61
- Technical
- Relative Strength Index (RSI)
- ONMD 33.54
- PMN 46.32
- Support Level
- ONMD $0.57
- PMN $0.72
- Resistance Level
- ONMD $0.77
- PMN $0.80
- Average True Range (ATR)
- ONMD 0.09
- PMN 0.09
- MACD
- ONMD -0.01
- PMN 0.01
- Stochastic Oscillator
- ONMD 27.08
- PMN 68.40
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data or iRWDTM. OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.